Meng Zhao, Ph.D.

Recent success in cancer immunotherapy, including using Chimeric Antigen Receptor (CAR) T cells and immune checkpoint blockade, has demonstrated clearly the power of treating human diseases by modulating the activity of T cells, an important population of white blood cells in humans. I am interested in a unique group of T cells, the innate-like T cells. While it takes days for conventional T cells to develop and become fully functional, innate-like T cells are rapid responders and first-line defenders against invading pathogens. When T cells go awry, however, it can attack one’s own body and cause autoimmune diseases, such as rheumatoid arthritis. Our research has recently shown that unlike the villainous T cells, the innate-like T cells are heroic and protect us from autoimmune arthritis. Innate-like T cells, therefore, are promising targets for new immunotherapy.

Our work has also shown that these T cells have distinctive ways to generate and use energy, as compared with mainstream T cells. The research in my lab is focused on understanding how the energetic processes control or regulate the important functions of innate-like T cells. Our discovery will provide new strategies to specifically target the innate-like T cells in human diseases and help design next-generation precision medicine.

My research interest is to understand the functions of innate-like T cells at the molecular level. These cell types, which share many features in common, include gd T cells, mucosal-associated invariant T (MAIT) cells and invariant natural killer T (iNKT) cells. These T lymphocytes are tissue homing and have rapid effector functions. They contain expanded populations in all individuals and will not cause graft-versus-host disease when transferred. Therefore, they are potential target populations for treating inflammatory diseases and for stimulating the responses to cancer. By defining the specific mechanisms underlying the unique functions of innate-like T cells, we can put forward new strategies for human immunotherapy.

Recently we have discovered that innate-like T cells exhibit distinct metabolic characteristics, which underlie the important functions of these cells during inflammation. We are interested in deciphering the mechanistic interaction between metabolic remodeling and immune functions in innate-like T cells during the pathogenesis of human diseases including autoimmune diseases and bacterial infections, in which we have shown that these cells play critical roles.

We will take advantage of cutting edge technologies including CRISPR-Cas9, novel genetically modified mouse models, metabolomic analysis, and single cell transcriptomic analysis. The long-term goal of our research is to understand the role of metabolic programs that regulate innate-like T cell response in human diseases.

Education
B.S., Wuhan University, Wuhan, HuBei, China, 2004
Ph.D., UT-Southwestern, Dallas, TX, 2010
Postdoctoral Fellow, UT-Southwestern, Dallas, TX, 2010
Postdoctoral Fellow, La Jolla Institute, La Jolla, CA, 2018

Honors and Awards
2013-2015 NIH Postdoctoral Fellowship on Rheumatic Diseases (1T32AR064194-01)
2018 AAI Young Investigator Award, La Jolla Immunology Conference
2019 Travel Grant: EMBO Workshop – CD1/MR1: Beyond MHC-restricted lymphocytes, Oxford University, UK

Coming soon

Email: Meng-Zhao@omrf.org

Maday Galeana Figueroa
Research Technician